Strategies for engineering oncolytic viruses to enhance cancer immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Non-small cell lung cancer (NSCLC) presents high mortality and metastasis challenges.
• Tumor microenvironment (TME) heterogeneity impacts anti-PD-1 immune checkpoint inhibitors (ICIs) efficacy.
• Varied patient responses to ICIs necessitate novel therapeutic strategies.

Purpose of the Study:

• To characterize oncolytic viruses (OVs) and their gene edits for NSCLC treatment.
• To explore strategies for enhancing anti-PD-1 therapy in NSCLC using engineered OVs.
• To propose a theoretically designed OV with a genomic framework to improve anti-PD-1 response.

Main Methods:

• Review of existing oncolytic virus strains and genetic modifications in NSCLC.
• Analysis of genomic adaptations for OV targeting in NSCLC.
• Identification of genetic factors influencing anti-PD-1 response variability.

Main Results:

• Insights into genomic adaptations for NSCLC-targeting OVs.
• Identification of genetic determinants for anti-PD-1 response variability.
• Proposal of genomic edits to enhance OV-mediated anti-PD-1 therapy effectiveness.

Conclusions:

• Engineered oncolytic viruses offer a promising strategy to enhance anti-PD-1 therapy in NSCLC.
• Understanding OV genomics is crucial for optimizing cancer immunotherapy.
• This work provides a framework for designing OVs to improve NSCLC treatment outcomes.